The bill inserts a narrowly drawn exception into the federal confidentiality statute that governs substance use disorder (SUD) treatment records, authorizing disclosure of records that "relate to the prescribing or dispensing of a substance use disorder medication" to a State's prescription drug monitoring program (PDMP) when an applicable State law requires it. In short: it permits SUD‑related medication records to flow to PDMPs, but only where state law mandates the disclosure.
This change is significant for treatment providers, prescribers, pharmacies, and PDMP operators because it expands a federal list of permitted disclosures that previously insulated much SUD treatment information. The amendment is narrow in wording but broad in potential operational impact: it creates a state‑conditioned pathway for PDMPs to receive SUD medication information, with downstream implications for privacy practices, consent forms, recordkeeping, and PDMP technical and legal readiness.
At a Glance
What It Does
The bill amends Section 543(b)(2) of the Public Health Service Act (42 U.S.C. 290dd–2(b)(2)) by adding a new clause that allows disclosure to a State PDMP of records related to prescribing or dispensing SUD medications when state law requires the disclosure.
Who It Affects
State PDMP administrators, clinicians and programs that prescribe or dispense medications for opioid or other SUDs, pharmacies, and state regulators charged with PDMP statutes and enforcement. Federal SUD confidentiality holders (programs funded under 42 U.S.C. 290dd–2) will face new decision points where state law diverges.
Why It Matters
It creates a federal authorization for a data flow that previously was constrained by SUD confidentiality rules, but only on a state‑law trigger—producing a patchwork risk across jurisdictions and pressing practical questions about definitions, consents, data handling, and provider liability.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The statutory change is concise: the bill adds an exception to the federal rule that limits disclosure of substance use disorder treatment records. That exception applies only to records that "relate to the prescribing or dispensing of a substance use disorder medication" and only when the disclosure is required by applicable state law.
The outcome is not an automatic federal mandate; instead, it clears a federal legal obstacle so that state statutes can, if they choose, compel SUD treatment programs or others holding those records to transmit relevant medication information into PDMPs.
Operationally, the amendment raises immediate questions for providers and programs about what records "relate to" SUD medication prescribing or dispensing. The bill does not define "substance use disorder medication" or supply data formats, consent processes, or minimum data elements.
That means organizations will need to interpret the phrase and reconcile it with existing confidentiality protections, consents, and electronic health record (EHR) systems. Programs that have treated SUD records as specially protected will have to review consent forms, internal access controls, and disclosures in states that adopt mandatory reporting rules.From the PDMP perspective, the statute gives states room to expand the scope of monitored data to include records that previously sat outside PDMP feeds.
States that choose to require disclosure will bear the technical and legal work of specifying what must be transmitted, who transmits it, and how to protect the information within PDMP systems. The bill is silent on enforcement mechanisms, penalties, or funding for system changes, so implementation will depend on state legislative choices and administrative guidance.Finally, the change is narrowly procedural rather than programmatic: it does not itself create a federal PDMP requirement, nor does it set national standards for privacy or data security.
Instead it creates a conditional federal permission slip: where a state law compels disclosure, federal SUD confidentiality will no longer bar the transfer of medication‑related records to that state's PDMP. That conditionality produces a legal landscape that will vary state by state and leave significant interpretive work to regulators, courts, and compliance officers.
The Five Things You Need to Know
The bill amends 42 U.S.C. 290dd–2(b)(2) (Public Health Service Act Section 543(b)(2)) by adding a new subclause (E).
The new clause permits disclosure to an "applicable prescription drug monitoring program of a State" when a record "relates to the prescribing or dispensing of a substance use disorder medication.", The federal authorization is expressly conditioned on the disclosure being "required by applicable State law"—disclosure is not authorized absent a state statutory or regulatory mandate.
The amendment targets records tied to SUD medication prescribing/dispensing (a narrower category than all SUD treatment records) rather than opening wholesale access to treatment files.
The bill is procedural: it removes a federal barrier to such disclosures but leaves states responsible for creating the mandatory disclosure rules, definitions, and operational requirements.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: "Safe Prescribing Through Reporting Act of 2025"
This section provides the act's short title for reference. It performs the usual identifying function and carries no substantive obligations.
Amendment to federal SUD confidentiality statute to allow PDMP disclosures
This is the operative provision. It appends a new paragraph (E) to the list of exceptions in Section 543(b)(2) of the Public Health Service Act (42 U.S.C. 290dd–2(b)(2)). That new paragraph authorizes disclosure of records to a State PDMP if the record relates to prescribing or dispensing a substance use disorder medication and if such disclosure is required by state law. Practically, the provision functions as a federal waiver of a confidentiality barrier—but only in the subset of cases that state law mandates reporting.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State PDMP administrators — Gain an explicit federal pathway to receive SUD medication‑related records where state law requires it, enabling more complete prescription surveillance if states opt in.
- State regulators and public health agencies — Obtain authority (via state law) to integrate SUD medication records into monitoring and program oversight, potentially improving detection of unsafe prescribing patterns.
- Pharmacies and prescribers in states that standardize reporting — Benefit from clearer legal footing for transmitting medication data to PDMPs when state law aligns reporting duties and protections.
Who Bears the Cost
- SUD treatment programs and clinicians — Face new compliance obligations in states that require disclosure, including updating consents, procedures, and recordkeeping practices; potential legal risk if they misapply the new exception.
- Patients receiving SUD medications — Bear increased exposure of sensitive treatment‑related data to PDMP systems, with attendant privacy and stigma risks that could affect treatment engagement.
- State agencies and PDMP operators — Must absorb the administrative, technical, and security costs of integrating new data sources, drafting implementing rules, and resolving legal and definitional ambiguities without federal funding in the bill.
Key Issues
The Core Tension
The central dilemma is privacy versus oversight: the bill permits greater PDMP access to information that helps detect unsafe prescribing and diversion, but it does so by chipping away at long‑standing special protections for SUD treatment records—potentially weakening patient privacy safeguards and deterring people from seeking care in states that require reporting.
The bill resolves one legal constraint by adding a targeted exception to federal SUD confidentiality, but it leaves key implementation questions unanswered. It does not define the scope of "substance use disorder medication," nor does it specify what it means for a record to "relate to" prescribing or dispensing.
Those gaps create interpretive burdens for providers and PDMPs: will clinic progress notes that mention a buprenorphine prescription be reportable, or only discrete prescription records? The absence of definitions increases litigation and compliance risk as stakeholders test boundaries in court or through agency guidance.
Another trade‑off is the state‑conditioned design: by tying federal permission to state mandates, the bill produces a patchwork across jurisdictions. That patchwork can hinder multi‑state providers, complicate EHR/PDMP interfaces, and create unequal privacy protections for patients depending on where they live or receive treatment.
The statute does not supply funding, data‑security standards, or federal preemption language to harmonize state decisions, so states that move to require reporting will need to navigate technical and legal issues on their own.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.